Price History

Hover for the daily close. The dotted line marks the period open.

Compare XCUR with… →

XCUR Key Statistics

As of Sep 4, 2026

Trading

Open: $1.23
Previous Close: $1.23
Day's Range: 1.22–1.28
52-Week Range: 1.05–9.48
Volume: 16.80K
Beta: 3.62

Valuation

Market Cap: $8.18M
P/E Ratio: unprofitable
EPS (ttm): −1.31

Financials (FY)

Revenue (FY): $0.00−100.00%
Net Income (FY): −$4.95M
Profit margin: 0.00%
Shares Outstanding: 6.55M
1-Year Return: −75.00%

Dividend and dates

Avg Volume: 406.88K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

XCUR Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−88.59%+371.38%−76.94%

2018*20192020202120222023202420252026*

Year	Return
2026 (partial year)	−76.94%
2025	−60.35%
2024	+371.38%
2023	−49.57%
2022	−81.02%
2021	−88.59%
2020	−38.11%
2019	−19.21%
2018 (partial year)	+14.19%

As of September 4, 2026.

XCUR Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$4.95M	—
2024	$500.00K	−$9.70M	−1940.2%
2023	$0.00	−$16.91M	—
2022	$28.83M	−$2.58M	−9.0%

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$10.12M	−$4.95M	—
2024	$500.00K	—	−$4.95M	−$9.70M	−1940.2%
2023	$0.00	—	−$13.14M	−$16.91M	—
2022	$28.83M	—	−$1.83M	−$2.58M	−9.0%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

XCUR Valuation vs Biotechnology Median

Median of 656 stocks

Metric	XCUR	Biotechnology median	vs median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

Exicure Plans To Issue 172,058 Common Shares To GPCR Therapeutics During This Month To Settle $1M Clinical Milestone Payment Obligation
Benzinga2026-08-03

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Exicure, Inc. (XCUR) at $8.18M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 1 employees.

Over the past 52 weeks the price has ranged from $1.05 to $9.48. The most recent close on file for XCUR is $1.25, dated September 4, 2026. That is +$0.02 (+1.63%) against the previous close. The latest close sits 19.05% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. Against the prior fiscal year total of $500.00K, that is a change of −100.00%. The same year closed with a net loss of $4.95M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −1.31.

Across the 4 fiscal years on file, revenue moves from $28.83M in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The reported beta is 3.62. Annualized volatility over the trailing 8 years is 131.65%. The trailing one-year price return is −75.00%. Measured over 5 years, that is −64.11% a year compounded.

Growth & Income

The record shows no dividend for XCUR.

2026 is still running; the price is −76.94% year to date. Across the complete calendar years on file, 2024 returned +371.38% and 2021 returned −88.59%. Of the 7 complete calendar years on file, 1 finished higher.

Peer Comparison

Exicure, Inc. (XCUR) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Exicure, Inc.	XCUR	$8.18M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Exicure, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Exicure, Inc.

Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.

Visit website →

Exicure, Inc. (XCUR) Stock Analysis